High5 with Dr. Igor Grant, MD
High5 with Dr. Igor Grant, MD
Podcast Description
Welcome to High5 with Dr. Igor Grant, Distinguished Professor of Psychiatry and Director of the Center for Medicinal Cannabis Research at UC San Diego. Each month, we’ll take you on a fascinating journey into the evolving world of medicinal cannabis. From groundbreaking research to candid conversations with top scientists and clinicians across the globe. In each episode, Dr. Grant poses five thought-provoking questions to his guest, uncovering their personal journey and unique contributions to the field of medicinal cannabis.
Podcast Insights
Content Themes
The podcast delves into various topics surrounding medicinal cannabis, including its impact on pain management, the role of neuroimaging in understanding substance use, and cardiovascular risks associated with cannabis use, with specific episodes discussing the Cannabis Act in Canada and its implications for the U.S. as well as the relationship between cannabis and driving impairment.
Welcome to High5 with Dr. Igor Grant, Distinguished Professor of Psychiatry and Director of the Center for Medicinal Cannabis Research at UC San Diego. Each month, we’ll take you on a fascinating journey into the evolving world of medicinal cannabis. From groundbreaking research to candid conversations with top scientists and clinicians across the globe. In each episode, Dr. Grant poses five thought-provoking questions to his guest, uncovering their personal journey and unique contributions to the field of medicinal cannabis.
Summary
In this conversation, Dr. Igor Grant and Dr. Eric Leas delve into the complexities surrounding Delta-8-THC, exploring its differences from Delta-9-THC, consumer demand, regulatory challenges, and safety concerns. They discuss the implications of state regulations on the market, the need for compliance in cannabis research, and the future of Delta-8-THC regulation. The conversation also touches on the broader landscape of cannabinoids and psychoactive substances, highlighting the ongoing evolution of cannabis regulation and public health considerations.
Takeaways
- Delta-8-THC is structurally similar to Delta-9-THC but less psychotropic effect.
- Consumer demand for Delta-8 is driven by its legal status as a hemp product in states without medical or recreational cannabis use regulations.
- Regulatory challenges exist due to the lack of standardized safety measures.
- States with legal cannabis markets are concerned about competition from Delta-8 products.
- Research on Delta-8 is limited, necessitating further studies on its effects.
- The market for Delta-8 is largely unregulated, raising safety concerns.
- There is a growing interest in other cannabinoids and psychoactive substances.
- Compliance checks in cannabis retail are complicated by federal laws.
- The patchwork of state regulations creates confusion for consumers and manufacturers.
Chapters:
00:00 Introduction to Delta-8 THC
02:51 Understanding Delta-8 THC: Differences and Similarities
05:15 Consumer Demand: Supply and Demand Dynamics
09:48 Regulatory Challenges and Safety Concerns
17:01 Research Background and Interest in Delta-8 THC
19:33 Compliance and Regulation in Cannabis Sales
21:50 Redesigning State and Federal Cannabis Policy
24:24 The Future of Delta-8 THC Regulation
27:39 Exploring Other Cannabinoids and Their Implications
32:25 The Broader Landscape of Psychoactive Substances
Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.